Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Isotope & Radiation Corp. ( (HK:1763) ) has provided an update.
China Isotope & Radiation Corporation announced that its subsidiary, CNNC Accuray, received 19 out of 28 deployment licenses for high-end radiotherapy equipment, specifically the CyberKnife, from the National Health Commission. This significant allocation is expected to expand CIRC’s market share and positively impact its operating results, reflecting strong industry and customer recognition.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation (CIRC) operates in the medical equipment industry, focusing on high-end radiotherapy equipment. The company, through its subsidiary CNNC Accuray, specializes in advanced oncology treatment devices like the CyberKnife, which integrates artificial intelligence and big data for precise radiotherapy services.
YTD Price Performance: 23.39%
Average Trading Volume: 159,192
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.06B
See more insights into 1763 stock on TipRanks’ Stock Analysis page.